Skip to content
Screener

Insight Molecular Diagnostics Inc. IMDX Q1 2025 earnings

Reported May 12, 2025 · After market close

Revenue$2.1MBeat by $2.0M
EPS-$0.26Miss by $0.02
Revenue estimate$126.8K
EPS estimate-$0.24

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$215.1K
EPS estimate-$0.23

Financials

Q1 2025

Income statement

See full
Revenue$2.1M+1,115%
Gross profit$1.3M+1,878%
Operating income-$6.8M+26.6%
Net income-$6.7M+26.9%
EPS (diluted)-$0.26+77.0%

Balance sheet

See full
Cash & equivalents$31.0M+456%
Total debt$3.3M—
Total equity$10.2M-11.8%
Total assets$60.4M-15.0%

Cash flow

See full
Operating cash flow-$5.8M-52.5%
CapEx$307.0K+1,179%
Free cash flow-$6.1M-59.5%

Valuation & ratios

Profitability

See full
Gross margin54.3%—
Operating margin-1,524.1%-492pp
Net margin-1,514.6%-488pp
FCF margin-611.4%—

Returns & leverage

See full
Return on equity-533.8%-942pp
Debt / equity0.3×—
Current ratio3.7×+3.0×

Segments

By geography

See full
Asia Pacific--100%

FAQ

When did Insight Molecular Diagnostics Inc. report Q1 2025 earnings?
Insight Molecular Diagnostics Inc. (IMDX) reported Q1 2025 earnings on May 12, 2025 after market close.
What were Insight Molecular Diagnostics Inc.'s Q1 2025 revenue and EPS?
Insight Molecular Diagnostics Inc. reported revenue of $2.1M and eps of $-0.26 for Q1 2025.
Did Insight Molecular Diagnostics Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $126.8K by $2.0M. EPS missed the consensus estimate of $-0.24 by $0.02.
How did Insight Molecular Diagnostics Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1114.8% from $176.0K a year earlier and eps grew 77.0% from $-1.13.
Where can I find Insight Molecular Diagnostics Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001641172-25-009681) and the 10-Q periodic report (0000950170-25-069213) directly on SEC EDGAR. The filing index links above go to sec.gov.